PMID- 19243286
OWN - NLM
STAT- MEDLINE
DCOM- 20090618
LR  - 20221207
IS  - 1744-7658 (Electronic)
IS  - 1354-3784 (Linking)
VI  - 18
IP  - 3
DP  - 2009 Mar
TI  - Exenatide once weekly for the treatment of type 2 diabetes.
PG  - 359-67
LID - 10.1517/13543780902766802 [doi]
AB  - Exenatide is the first glucagon-like peptide-1 (GLP-1) receptor agonist approved 
      for the treatment of type 2 diabetes mellitus (T2DM). Exenatide lowers blood 
      glucose through multiple mechanisms, including enhancement of glucose-dependent 
      insulin secretion, suppression of excess glucagon secretion, reduction of food 
      intake and slowing of gastric emptying. The current formulation of exenatide 
      requires twice-daily dosing (exenatide BID), and an extended-release formulation 
      of exenatide is now in development for use as a once-weekly injection (exenatide 
      QW). The purpose of this report is to review the most current clinical data on 
      the development of exenatide QW for the treatment of T2DM. In clinical trials, 
      exenatide QW significantly improved glycemic control, resulted in patient weight 
      loss, and was well tolerated in patients with T2DM. In a head-to-head clinical 
      trial, exenatide QW caused greater improvements in glycemic control and was 
      better tolerated than exenatide BID. Given the rapidly increasing prevalence of 
      diabetes and obesity worldwide, exenatide QW is a promising development candidate 
      for the treatment of T2DM.
FAU - Malone, James
AU  - Malone J
AD  - Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, IN 46285, USA. 
      jkmalone@lilly.com
FAU - Trautmann, Michael
AU  - Trautmann M
FAU - Wilhelm, Ken
AU  - Wilhelm K
FAU - Taylor, Kristin
AU  - Taylor K
FAU - Kendall, David M
AU  - Kendall DM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Investig Drugs
JT  - Expert opinion on investigational drugs
JID - 9434197
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Peptides)
RN  - 0 (Venoms)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 9P1872D4OL (Exenatide)
SB  - IM
MH  - Animals
MH  - Clinical Trials as Topic
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Drug Tolerance
MH  - Exenatide
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Peptides/*administration & dosage/chemistry/pharmacology/*therapeutic use
MH  - Treatment Outcome
MH  - Venoms/*administration & dosage/chemistry/pharmacology/*therapeutic use
RF  - 57
EDAT- 2009/02/27 09:00
MHDA- 2009/06/19 09:00
CRDT- 2009/02/27 09:00
PHST- 2009/02/27 09:00 [entrez]
PHST- 2009/02/27 09:00 [pubmed]
PHST- 2009/06/19 09:00 [medline]
AID - 10.1517/13543780902766802 [doi]
PST - ppublish
SO  - Expert Opin Investig Drugs. 2009 Mar;18(3):359-67. doi: 
      10.1517/13543780902766802.